Key Highlights
- TTRX shares rose approximately 25% in trading today to $9.59, up from a prior close of $7.69.
- The company announced its final Stage 2 study design for GX-03 in atopic dermatitis, expanding enrollment to the full spectrum of disease severity.
- The Stage 2 population will include approximately 120 to 135 patients evaluated across four prespecified efficacy endpoints.
- No treatment-related serious adverse events have been observed to date, and GX-03 continues to show a favorable tolerability profile.
Interim Review Expands Patient Population
Turn Therapeutics, Inc. (NASDAQ:TTRX) shares surged in trading today after the company announced the completion of a comprehensive interim analysis of its adaptive Phase 2 trial evaluating GX-03 for atopic dermatitis. Turn Therapeutics is a Westlake Village, California-based clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases.
The interim review, conducted under the oversight of an Independent Data Monitoring Committee, identified clinically meaningful efficacy across a broader spectrum of disease severity than originally anticipated. As a result, the final Stage 2 design will prospectively evaluate patients across the full baseline Eczema Area and Severity Index spectrum, stratified into three severity groups, using the FDA-recognized Hochberg multiple testing procedure across four prespecified efficacy endpoints rather than a single primary endpoint.
Trial Design Details and Financial Position
The final Stage 2 population will include approximately 120 to 135 patients, with 1:1 randomization maintained within each severity stratum. The review confirmed that Week 4 provided the earliest and clearest treatment separation between GX-03 and vehicle, supporting the inclusion of early efficacy endpoints in the final design. Enrollment continued uninterrupted throughout the review, with all patients enrolled during that period remaining blinded and incorporated into the final Stage 2 analysis.
Turn Therapeutics carries a market capitalization of approximately $285.67 million following today's gain, with shares trading within a 52-week range of $2.57 to $26.50. The company reported it remains sufficiently capitalized to support completion of the study and planned operations through the third quarter of 2027, with enrollment expected to complete during the fourth quarter of 2026.
Conclusion
Today's gain reflects investor enthusiasm around the expanded trial design, which broadens the potential commercial opportunity for GX-03 beyond the originally anticipated patient population. Investors will likely watch enrollment progress toward the expected fourth-quarter 2026 completion, along with any interim efficacy signals as the trial advances.
FAQs
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...